GlassScriptPhysician profile
Noah H Starkey
NPI 1376648345
$18,634.13
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,739 · 2020: $3,396 · 2021: $4,127 · 2022: $3,449 · 2023: $3,076 · 2024: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,916 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.24 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,821.13 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,457.48 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $2,367.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,152.27 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,144.63 | 2019-2024 | Breztri, Farxiga, Bevespi Aerosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $862.73 | 2019-2023 | Jardiance, Stiolto Respimat |
| Allergan, INC. | $779.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.15 | 2019-2024 | Xifaxan |
| Pfizer INC. | $588.77 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $548.73 | 2019-2021 | |
| Amgen INC. | $391.77 | 2019-2023 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $380.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $371.17 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $315.62 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.18 | 2019-2023 | Glassia |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Starkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.